Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Unicycive Therapeutics, Inc. (UNCY) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Unicycive is a clinical-stage biotechnology company developing therapies for kidney diseases, and its filings offer structured insight into the progress of oxylanthanum carbonate (OLC) and UNI-494, as well as its capital markets activities and corporate governance.
Investors can review Form 8-K current reports where Unicycive discloses material events such as receipt of a Complete Response Letter for the OLC New Drug Application, updates from FDA Type A meetings, NDA resubmission timing, reverse stock split implementation, at-the-market equity offering amendments, preliminary financial information, and Nasdaq listing compliance. Certain 8-Ks also reference press releases on financial results, clinical data publications, and legal proceedings, including a purported securities class action related to public statements about the OLC NDA.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader detail on Unicycive’s kidney disease pipeline, risk factors, research and development spending, general and administrative expenses, and descriptions of oxylanthanum carbonate and UNI-494, including orphan drug designation for prevention of delayed graft function in kidney transplant patients. These periodic filings also summarize the company’s status as an emerging growth company and its listing on the Nasdaq Capital Market under the symbol UNCY.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting key sections on regulatory milestones, capital structure changes such as reverse stock splits, at-the-market programs, and disclosed cash positions and runway commentary. Users can quickly locate discussions of OLC’s regulatory path, UNI-494 patents and designations, and updates that management reports through 8-Ks and other forms, enabling a more efficient review of Unicycive’s SEC reporting history.
Unicycive Therapeutics, Inc. disclosed that, after June 30, 2025, it sold 3,549,846 shares of common stock under a sales agreement with Guggenheim Securities, LLC. The shares were sold at an average price of
This at-the-market style equity financing increases Unicycive’s cash resources but also adds new shares to its common stock base. The filing does not detail specific uses for the funds, only that the proceeds were received by the company.
Great Point Partners, LLC and two associated individuals filed a Schedule 13G/A reporting joint beneficial ownership of 796,558 shares of Unicycive Therapeutics, Inc. common stock, representing 6.24% of the 12,768,239 shares outstanding cited from the issuer's June 20, 2025 filing. The filing shows shared voting and dispositive power over those shares and no sole voting or dispositive power. The record holders are Biomedical Value Fund, L.P. (510,494 shares) and Biomedical Offshore Value Fund, Ltd. (286,064 shares); Great Point is investment manager of both and disclaims beneficial ownership except to the extent of pecuniary interests. The Reporting Persons executed a Joint Filing Agreement dated August 14, 2025, and certified the holdings were not acquired to change or influence control.
Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 1,234,596 shares of Unicycive Therapeutics, Inc. (CUSIP 90466Y103), representing 9.99% of the outstanding common stock as of June 30, 2025. The reported total includes 295,394 shares that may be acquired within 60 days upon exercise of warrants. Nantahala is identified as an investment adviser and Messrs. Harkey and Mack file as control persons in respect of shares held by funds and managed accounts under Nantahala's control. Blackwell Partners LLC - Series A, a fund advised by Nantahala, has rights to dividends or sale proceeds for more than 5% of the shares reported.
Biotechnology Value Fund and affiliated entities reported beneficial ownership positions in Unicycive Therapeutics (UNCY) as of June 30, 2025. The filing discloses adjusted holdings after a one-for-ten reverse stock split and extensive warrant positions that convert into Series A preferred stock and then into common shares subject to a 9.99% beneficial ownership limitation. Individual reported holdings: BVF 777,308 shares (~5.7%), BVF II 591,650 shares (~4.4%), Trading Fund OS 35,480 shares (<1%), and affiliated entities collectively up to 1,417,117 shares (~9.99%). The statement explains which warrant tranches (A, B, C) are exercisable, exercise-price relationships and that the Beneficial Ownership Limitation restricts conversion of some tranches (notably Tranche C).
Unicycive Therapeutics reported that it has issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. The company furnished that press release as Exhibit 99.1 to its Form 8-K and clarified the disclosure is being furnished, not filed for purposes of the Exchange Act and will not be incorporated by reference into registration statements, except as expressly stated. The Form 8-K also identifies the company as an emerging growth company.
Unicycive Therapeutics (UNCY) reported interim financial results for the quarter ended June 30, 2025 showing $22.3 million in cash and total assets of $30.0 million, down slightly from $31.7 million at year-end. Total liabilities fell materially to $13.6 million from $24.2 million, driven largely by a decline in the warrant liability from $18.9 million to $10.2 million, which reduced reported expense volatility.
The company recorded a six-month net loss of $5.9 million, an improvement from a $11.1 million loss in the prior-year period, as operating expenses decreased to $15.0 million from $16.6 million. Cash used in operating activities was $17.3 million for the six months, and net cash provided by financing activities was $13.5 million, including $12.6 million from a secondary offering. Management states it believes it has sufficient resources for at least one year under current plans. The filing also discloses a 1-for-10 reverse stock split effective June 20, 2025 and ongoing reliance on future financing to complete development and commercial efforts.
Octagon Capital Advisors LP and related funds and principal Ting Jia report beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. (UNCY), representing 7.8% of the outstanding common stock based on 12,768,239 shares outstanding as reported by the issuer. Octagon is the investment manager of the funds and Mr. Jia is the managing member of Octagon, and by virtue of those relationships Octagon and Mr. Jia may be deemed to beneficially own the shares held by the funds.
The filing discloses that the reported holdings are held with shared voting and dispositive power rather than sole power. The ownership is allocated as 650,000 shares (5.1%) held by Octagon Investments Master Fund LP and 350,000 shares (2.7%) held by Octagon Private Opportunities Fund II LP. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.